---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-022582"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2026-01-26T23:59:59+00:00"
generated_at: "2026-05-16T08:00:25.004142+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Mirum acquires Bluejay for $280.8M cash + stock; adds late-stage HDV therapy

## Summary
- Upfront consideration $280.8M cash plus ~4.67M shares; holdback $25.8M plus ~0.52M shares; up to $200M milestones.
- Added brelovitug (anti-HDV mAb) with FDA Breakthrough Therapy and EMA PRIME; Phase 3 AZURE topline data expected 2H 2026.
- Concurrent private placements raised ~$268.5M gross proceeds to support brelovitug development and commercial activities.
- Mirum also acquired Bluejay's net cash of ~$56.6M.
- Entities affiliated with Frazier Life Sciences (board member >5% holder) received pro rata portion of consideration.

## SEC filing metadata
- accession: 0001193125-26-022582
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2026-01-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000119312526022582/0001193125-26-022582-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000119312526022582/d35336d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-022582
- JSON: https://secwatch.observer/filing/0001193125-26-022582.json
- Plain text: https://secwatch.observer/filing/0001193125-26-022582.txt

## Source-grounded claims
- claim_id: 799661d3527c496b22f4041de76d5d22e4071644
  claim: Mirum Pharmaceuticals, Inc. completed an acquisition involving Bluejay Therapeutics, Inc. for up to an aggregate amount of (i) $280.8 million in cash and (ii) 4,673,597 shares of Company common stock (closed 2026-01-23).
  evidence_excerpt: of the Mergers, the Company acquired Target’s net cash of approximately $56.6 million and paid or will pay to the holders of Target’s securities up to an aggregate amount of (i) $280.8 million in cash and (ii) 4,673,597 shares of Company common stock, subject to the Company’s receipt of deliverables that are a condition to payment and deduction to satisfy applicable
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000119312526022582/0001193125-26-022582-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.